Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor

Curr Opin Investig Drugs. 2006 Aug;7(8):759-65.

Abstract

Panacos Pharmaceuticals Inc is developing the HIV Gag protein and viral maturation inhibitor bevirimat for the potential oral treatment of HIV infection. Phase II clinical trials are underway and phase III trials expected to commence in 2007.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials, Phase II as Topic
  • Drug Evaluation, Preclinical
  • Gene Products, gag / antagonists & inhibitors*
  • HIV Infections / drug therapy*
  • HIV Infections / metabolism
  • HIV-1 / metabolism*
  • Humans
  • Succinates / adverse effects
  • Succinates / pharmacokinetics
  • Succinates / pharmacology*
  • Succinates / therapeutic use
  • Triterpenes / adverse effects
  • Triterpenes / pharmacokinetics
  • Triterpenes / pharmacology*
  • Triterpenes / therapeutic use

Substances

  • Gene Products, gag
  • Succinates
  • Triterpenes
  • bevirimat